Arcutis Biotherapeutics, Inc. (ARQT)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 4 | 60 | 197 | 376 | 464 | 537 |
| Operating profit | $m | -12 | 34 | ||||||
| Net profit | $m | -136 | -206 | -311 | -262 | -140 | -16 | 29 | 57 |
| EPS reported | $ | -0.13 | 0.21 | ||||||
| Operating cashflow per share | $ | -0.04 | 0.30 | ||||||
| Capex per share | $ | 0.01 | 0.00 | ||||||
| FCF per share | $ | -0.05 | 0.30 | ||||||
| Free cash flow | $m | -6 | 39 | ||||||
| Net debt | $m | -215 | -130 | ||||||
| Book value equity | $m | 189 | 221 | ||||||
| Book value per share | $ | 1.49 | 1.62 | ||||||
| Number of shares | m | 127.23 | 135.9 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | 131.08 | ||||||
| P/B LTM | x | 19.50 | 16.75 | ||||||
| P/S LTM | x | 9.82 | 7.96 | ||||||
| P/FCF LTM | x | -585.47 | 94.37 | ||||||
| EV/EBITDA LTM | x | 1,475.09 | 82.90 | ||||||
| EV/Sales LTM | x | 9.73 | 6.62 | ||||||
| Earnings Yield LTM | % | -0.44% | +0.76% | ||||||
| FCF Yield | % | -0.17% | +1.06% | ||||||
| Quality | |||||||||
| ROE | % | -8.52% | +15.05% | ||||||
| ROIC | % | -4.02% | +9.95% | ||||||
| Operating margin | % | -3.25% | +7.38% | ||||||
| Gross margin | % | +90.24% | +91.14% | ||||||
| FCF/Sales | % | -1.68% | +8.44% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +91.34% | +136.07% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -1.01 | 0.34 | ||||||
| Net Debt/EBITDA | x | -14.77 | 1.81 | ||||||
| EBIT/Net interest | x | -1.01 | 2.47 | ||||||
| Net debt/market cap | % | +0.17% | +3.64% | ||||||
| Net debt/Equity | x | -1.13 | -0.59 | ||||||
| Gross debt/equity | x | 0.03 | 0.52 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Arcutis Biotherapeutics, Inc. (ARQT)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free